← Eichor
Study identifier: NCT05562947 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Condition: Neovascular Age-related Macular Degeneration · nAMD  ·  Sponsor: Hoffmann-La Roche

PhasePhase 3
Planned participants68
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.

This description comes directly from the study's public registry record.

Talk to the study team

Reference Study ID Number: YR42983 https://forpatients.roche.com/ No attachments to email below.  ·  888-662-6728 (U.S. and Canada)  ·  global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Always discuss trial participation with your own doctor first.

Locations (16)

Peking Union Medical College HospitalBeijing, ChinaRecruiting
Beijing HospitalBeijing, ChinaWithdrawn
Beijing Tongren HospitalBeijing, ChinaRecruiting
West China Hospital, Sichuan UniversityChengdu, ChinaRecruiting
Sichuan Provincial People's HospitalChengdu, ChinaRecruiting
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityGuangzhou, ChinaRecruiting
The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaRecruiting
Qingdao Eye Hospital of Shandong First Medical UniversityQingdao, ChinaRecruiting
Shanghai First People's HospitalShanghai, ChinaRecruiting
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaWithdrawn
The First Affiliated Hospital of China Medical UniversityShenyang, ChinaRecruiting
Shanxi Eye HospitalTaiyuan, ChinaRecruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05562947